LOGIN  |  REGISTER
Astria Therapeutics

Zynex Recognized in The Power 500 Healthcare Technology Companies

January 31, 2023 | Last Trade: US$8.26 0.15 1.85

ENGLEWOOD, Colo., Jan. 31, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex in The Power 500 Healthcare Technology Companies. 

"We are honored to be included in The Power 500 alongside some of the most innovative and well-known organizations in healthcare. Zynex ranked 27th among medical device companies and we believe this distinction solidifies our position as leaders in the category," said Thomas Sandgaard, CEO of Zynex. "Our consistent operational performance is the result of a committed team striving to improve the health of our patients. I'm proud of this recognition and look forward to many years of innovation and growth."

About The Healthcare Technology Report

The Healthcare Technology Report (HLTR) provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com

Investor Contact
Gilmartin Group
650 Fifth Ave., Suite 2720
New York, NY 10019
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB